Literature DB >> 23619961

Is there a role for combination therapy for osteoporosis?

Felicia Cosman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23619961     DOI： 10.1007/s12020-013-9954-6

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  15 in total

1.  Daily and cyclic parathyroid hormone in women receiving alendronate.

Authors:  Felicia Cosman; Jeri Nieves; Marsha Zion; Lillian Woelfert; Marjorie Luckey; Robert Lindsay
Journal:  N Engl J Med       Date:  2005-08-11       Impact factor: 91.245

2.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Authors:  Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens; Christian Kasperk; Philemon Papanastasiou; Aimee Readie; Hanumantha Rao; Jürg A Gasser; Christina Bucci-Rechtweg; Steven Boonen
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

Review 3.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

4.  Combination therapy with risedronate and teriparatide in male osteoporosis.

Authors:  Marcella D Walker; Natalie E Cusano; James Sliney; Megan Romano; Chiyuan Zhang; Donald J McMahon; John P Bilezikian
Journal:  Endocrine       Date:  2012-10-26       Impact factor: 3.633

5.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

6.  Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Authors:  Felicia Cosman; Tony M Keaveny; David Kopperdahl; Robert A Wermers; Xiaohai Wan; Kelly D Krohn; John H Krege
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

7.  Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.

Authors:  Christian Muschitz; Roland Kocijan; Astrid Fahrleitner-Pammer; Solveig Lung; Heinrich Resch
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

8.  The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Authors:  E S Orwoll; W H Scheele; S Paul; S Adami; U Syversen; A Diez-Perez; J M Kaufman; A D Clancy; G A Gaich
Journal:  J Bone Miner Res       Date:  2003-01       Impact factor: 6.741

9.  Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Authors:  Bruce Ettinger; Javier San Martin; Gerald Crans; Imre Pavo
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

10.  Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Authors:  Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958
View more
  1 in total

1.  Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.

Authors:  J Pepe; A M Isidori; M Falciano; G Iaiani; A Salotti; D Diacinti; R Del Fiacco; E Sbardella; C Cipriani; S Piemonte; O Raimo; P Biondi; F Biamonte; A Lenzi; S Minisola
Journal:  Endocrine       Date:  2014-08-08       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.